Leerink Partners Sticks to Their Hold Rating for Blueprint Medicines (BPMC)
In a report released yesterday, Andrew Berens from Leerink Partners maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price target of $129.00. The company’s shares closed yesterday at $128.10.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Berens is an analyst with an average return of -4.5% and a 39.79% success rate. Berens covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Incyte, and Elevation Oncology.
In addition to Leerink Partners, Blueprint Medicines also received a Hold from Citi’s David Lebowitz in a report issued yesterday. However, on June 3, Robert W. Baird maintained a Buy rating on Blueprint Medicines (NASDAQ: BPMC).
The company has a one-year high of $128.15 and a one-year low of $73.04. Currently, Blueprint Medicines has an average volume of 2M.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
Read More on BPMC:
Disclaimer & DisclosureReport an Issue
- Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Blueprint Medicines upgraded to Neutral from Sell at Citi
- Blueprint Medicines downgraded to Neutral from Buy at Guggenheim
- Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
- Blueprint Medicines downgraded to Equal Weight from Overweight at Stephens
